The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
A 2026 meta-analysis of 40 randomized trials involving more than 23,000 participants found no statistically significant mortality benefit in hospitalized or outpatient treatment groups.
The 2026 review pooled four prevention and 36 treatment randomized trials, not 40 treatment trials; hospitalization and mortality outcomes, risk-of-bias and a proposed early-era ventilation subgroup still need individual verification.